Genomes and Genes
Nigel J Bundred
Affiliation: University of Manchester
- Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred
Department of Academic Surgery, Education and Research Centre, University Hospital of South Manchester, Wythenshawe, M23 9LT Manchester, UK
Invest New Drugs 31:949-58. 2013..Despite low olaparib exposure, PARP inhibition was consistent with previous reports. Reasons for the inter-study differences in exposure are unclear. The tolerability profile of olaparib was consistent with previous studies...
- Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?Nigel J Bundred
Academic Department of Surgery, University Hospital of South Manchester, 2nd Floor Education and Research Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
Breast Cancer Res Treat 138:359-68. 2013..SDBC have lower mortality than symptomatic due to a lower proliferative index. The use of adjuvant chemotherapy is over-treatment for ER positive SDBCs with Good Prognostic Group (GPG) and MPG1 NPI scores...
- Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudyNigel J Bundred
Department of Surgery, University of Manchester, Southmoor Road, Manchester, M23 9LT, UK
Breast Cancer Res 14:R13. 2012..40 (95% CI, 1.14 to 1.70; P = 0.001). A subgroup of women was entered into a study of bone mineral density (BMD)...
- Aromatase inhibitors and bone healthNigel J Bundred
University Hospital of South Manchester, Education and Research Centre, Wythenshawe, Manchester, UK
Curr Opin Obstet Gynecol 21:60-7. 2009..Aromatase inhibitors improve survival in breast cancer patients but adversely affect bone health...
- Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trialNigel J Bundred
Department of Academic Surgery, University Hospital of South Manchester, Manchester, United Kingdom
Clin Cancer Res 16:1605-12. 2010..The primary end point was a decrease in Ki67 between diagnosis and surgical excision...
- Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breastNicola L P Barnes
Department of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom
Clin Cancer Res 11:2163-8. 2005..Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS...
- Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinomaRamachandran Prasad
Department of Surgery, University Hospital of South Manchester, Manchester, United Kingdom
Cancer 98:2539-46. 2003..The goal of rhe current study was to determine the short-term effect of HRT withdrawal on invasive breast carcinoma using biologic surrogate markers of tumor response...
- Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivoFredrik Warnberg
Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
Breast Cancer Res 8:R21. 2006..Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested...
- Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathwaysGillian Farnie
Department of Surgery and Breast Biology Group, Division of Cancer Studies, Faculty of Medicine and Human Sciences, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, M20 9BX, Manchester, UK
J Natl Cancer Inst 99:616-27. 2007..We investigated the involvement of these signaling pathways in ductal carcinoma in situ (DCIS) of the breast...
- Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancerFiona M Foster
Faculty of Life Sciences, University of Manchester, Manchester, UK
Breast Cancer Res 11:R41. 2009..Here we examine the levels of IAPs in breast cancer and evaluate whether targeting IAPs can enhance apoptosis in response to growth factor receptor antagonists and TRAIL...
- Molecular markers and therapeutic targets in ductal carcinoma in situGary P Boland
Department of Academic Surgery, University Hospital of South Manchester, M23 9LT UK
Microsc Res Tech 59:3-11. 2002..Blockade of the pathways involved in cell proliferation in ER-negative DCIS is possible and will be necessary to prevent ER-negative breast cancers if the goal of breast cancer chemoprevention is to be realistically achieved...
- Targeting IL-8 signalling to inhibit breast cancer stem cell activityJagdeep K Singh
University of Manchester, Institute of Cancer Sciences, Paterson Institute for Cancer Research, Breast Biology Group, Wilmslow Road, Manchester, M20 4BX, UK 44 161 446 3210
Expert Opin Ther Targets 17:1235-41. 2013..Here, we discuss the role of IL-8 in breast CSC regulation and development of novel therapies to target CXCR1/2 signalling in breast cancer. ..
- Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred
South Manchester University Hospital, Academic Surgery, Education and Research Center, Manchester, UK
Cancer 112:1001-10. 2008..This study evaluated an immediate or delayed strategy of bone protection therapy with zoledronic acid...
- Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 statusGillian Farnie
Cancer Stem Cell Research, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, the Christie NHS Foundation Trust, Manchester, United Kingdom
PLoS ONE 8:e56840. 2013..These data provide further understanding of DCIS biology and suggest treatment strategies combining Notch and ErbB1/2 inhibitors should be investigated regardless of ErbB2 receptor status...
- Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanismsJagdeep K Singh
Breast Biology Group, Institute of Cancer Sciences, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom
Clin Cancer Res 19:643-56. 2013..We investigated the role of IL-8 in the regulation of CSC activity using patient-derived breast cancers and determined the potential benefit of combining CXCR1/2 inhibition with HER2-targeted therapy...
- To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?Julie Iddon
University Hospital of South Manchester NHS Foundation Trust, Education and Research Centre, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
Expert Rev Anticancer Ther 8:9-13. 2008..Switching to exemestane for patients who have already had tamoxifen therapy for 2-3 years would appear to be an appropriate strategy for the majority of early breast cancer patients...
- Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifenNigel J Bundred
Department of Surgery, South Manchester University Hospital Education and Research Centre, UK
Anticancer Res 22:2317-9. 2002..This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis...
- Letrozole: a well-tolerated and effective treatment for breast cancerNigel J Bundred
South Manchester University Hospital, Education and Research Centre, Southmoor Road, Manchester, M23 9LT, UK
Womens Health (Lond Engl) 2:673-85. 2006..Overcoming the development of resistance to endocrine therapy is under investigation. As a potent aromatase inhibitor, letrozole is the ideal drug for tailored combination treatment regimens of the future...
- Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastKai C Chan
Department of Surgery, University Hospital of South Manchester, United Kingdom
Cancer Res 62:122-8. 2002..3; P = 0.0005]. EGFR-TK inhibition with ZD1839 offers a novel approach to the treatment of EGFR-positive DCIS, regardless of ER status, and provides a potential new chemopreventative approach in patients at high risk of breast cancer...
- Do early premalignant changes in normal breast epithelial cells predict cancer development?Robert B Clarke
CR UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
Breast Cancer Res 7:18-20. 2005....
- Idiopathic granulomatous mastitis: a 25-year experienceBilal Al-Khaffaf
Department of Academic Surgery, Wythenshawe Hospital, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom
J Am Coll Surg 206:269-73. 2008..Eighteen patients with a histopathologic diagnosis of IGM, seen over a period of 25 years, were retrospectively reviewed and compared with 133 patients with PDM and 100 normal patients...
- Response and resistance to the endocrine prevention of breast cancerAnthony Howell
CRC Department Medical Oncology, University of Manchester Christie Hospital and Holt Radium Inst, Manchester, UK
Adv Exp Med Biol 617:201-11. 2008....